Darbepoetin Alfa
drugOn this page
Also known as AranespAranesp sureclickDA-3880Da3880DarbepoetinrecombinantDarbepoetina alfaDarbepoetine alfaKRN-321KRN321NESPNespo
Summary
Darbepoetin Alfa (CHEMBL1201566) is an approved protein (ATC B03XA02); indicated across 21 conditions including anemia and chronic kidney disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: B03XA02
- Indications: 21 conditions
- Clinical trials: 161
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201566 |
| Name | Darbepoetin Alfa |
| Type | Protein |
| Max phase | 4 |
| ATC | B03XA02 |
Also known as: Aranesp, Aranesp sureclick, DA-3880, Da3880, Darbepoetin, Darbepoetin alfa, recombinant, Darbepoetina alfa, Darbepoetine alfa, KRN-321, KRN321, NESP
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
21 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| anemia | 4 | MONDO:0002280 | EFO:0004272 |
| chronic kidney disease | 4 | MONDO:0005300 | EFO:0003884 |
| neoplasm | 4 | MONDO:0005070 | MONDO:0004992 |
| diffuse large B-cell lymphoma | 3 | MONDO:0018905 | EFO:0000403 |
| myelodysplastic syndrome | 3 | MONDO:0018881 | EFO:0000198 |
| small cell lung carcinoma | 3 | MONDO:0008433 | EFO:0000702 |
| kidney disorder | 3 | MONDO:0005240 | EFO:0003086 |
| myocardial infarction | 3 | MONDO:0005068 | EFO:0000612 |
| breast neoplasm | 3 | MONDO:0021100 | MONDO:0007254 |
| B-cell chronic lymphocytic leukemia | 3 | MONDO:0004948 | EFO:0000095 |
| acute myocardial infarction | 3 | MONDO:0004781 | EFO:0008583 |
| leukemia | 2 | MONDO:0005059 | EFO:0000565 |
| lymphoma | 2 | MONDO:0005062 | EFO:0000574 |
| lymphoid neoplasm | 2 | MONDO:0005157 | EFO:0001642 |
| acute kidney injury | 2 | MONDO:0002492 | HP:0001919 |
| dysgerminoma | 2 | MONDO:0003002 | MONDO:0003002 |
| brain ischemia | 2 | MONDO:0005299 | MONDO:0005299 |
| brain injury | 2 | MONDO:0043510 | MONDO:0043510 |
| brain disorder | 2 | MONDO:0005560 | HP:0001298 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 161.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 73 |
| PHASE2 | 44 |
| PHASE4 | 16 |
| Not specified | 12 |
| PHASE1 | 9 |
| PHASE1/PHASE2 | 4 |
| PHASE2/PHASE3 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07025460 | PHASE4 | ACTIVE_NOT_RECRUITING | Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis: A Multicenter, Phase 4 Study |
| NCT00117117 | PHASE4 | COMPLETED | A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp® |
| NCT00122720 | PHASE4 | COMPLETED | The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery |
| NCT00153868 | PHASE4 | COMPLETED | A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer |
| NCT00315484 | PHASE4 | COMPLETED | Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia |
| NCT00368901 | PHASE4 | COMPLETED | STAAR-2 Clinical Study |
| NCT00369733 | PHASE4 | COMPLETED | STAAR-3 Clinical Study |
| NCT00369772 | PHASE4 | COMPLETED | STAAR-1 Clinical Study |
| NCT00377481 | PHASE4 | COMPLETED | COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia. |
| NCT00773513 | PHASE4 | COMPLETED | A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs) |
| NCT01306409 | PHASE4 | COMPLETED | Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA) |
| NCT01506947 | PHASE4 | COMPLETED | A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients |
| NCT02049346 | PHASE4 | COMPLETED | Comparison Among Erythropoietin Stimulating Agents |
| NCT02817555 | PHASE4 | COMPLETED | Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients |
| NCT04959578 | PHASE4 | COMPLETED | Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease |
| NCT05864261 | PHASE4 | COMPLETED | Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers |
| NCT06466785 | PHASE3 | RECRUITING | A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis |
| NCT07169643 | PHASE3 | RECRUITING | Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial) |
| NCT07300111 | PHASE3 | NOT_YET_RECRUITING | A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) |
| NCT00038064 | PHASE3 | COMPLETED | Anemia in Patients With a Non-Myeloid Malignancy |
| NCT00070382 | PHASE3 | COMPLETED | Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer |
| NCT00077766 | PHASE3 | COMPLETED | A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients. |
| NCT00081471 | PHASE3 | COMPLETED | A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis |
| NCT00090753 | PHASE3 | COMPLETED | A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia |
| NCT00091858 | PHASE3 | COMPLETED | Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer |
| NCT00093015 | PHASE3 | COMPLETED | Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT) |
| NCT00096915 | PHASE3 | COMPLETED | Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis |
| NCT00110955 | PHASE3 | COMPLETED | Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy |
| NCT00111098 | PHASE3 | COMPLETED | Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis |
| NCT00111137 | PHASE3 | COMPLETED | Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy |
| NCT00115167 | PHASE3 | COMPLETED | A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study |
| NCT00117624 | PHASE3 | COMPLETED | A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy |
| NCT00119587 | PHASE3 | COMPLETED | Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects |
| NCT00119613 | PHASE3 | COMPLETED | A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa |
| NCT00121602 | PHASE3 | COMPLETED | Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease |
| NCT00135317 | PHASE3 | COMPLETED | AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies |
| NCT00144755 | PHASE3 | COMPLETED | R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma |
| NCT00148421 | PHASE3 | COMPLETED | Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy. |
| NCT00213291 | PHASE3 | COMPLETED | Darbepoetin Treatment of Anemia in Children With Chronic Renal Failure |
| NCT00234143 | PHASE2/PHASE3 | UNKNOWN | Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).